SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Van Plew Daniel P

(Last) (First) (Middle)
777 OLD SAW MILL RIVER ROAD

(Street)
TARRYTOWN NY 10591

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & General Mgr, Industrial
3. Date of Earliest Transaction (Month/Day/Year)
02/14/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/14/2024 S 439 D $937.94(1) 30,373 D
Common Stock 02/14/2024 S 226 D $938.13(2) 30,147 D
Common Stock 02/14/2024 S 750 D $939.6(3) 29,397 D
Common Stock 02/14/2024 S 4,261 D $940.44(4) 25,136 D
Common Stock 02/14/2024 S 275 D $941.41(5) 24,861 D
Common Stock 02/14/2024 S 2,691 D $943.51(6) 22,170 D
Common Stock 02/14/2024 S 620 D $944.3(7) 21,550 D
Common Stock 02/14/2024 S 95 D $945.81(8) 21,455 D
Common Stock 02/14/2024 S 240 D $947.81(9) 21,215 D
Common Stock 02/14/2024 S 150 D $948.7(10) 21,065 D
Common Stock 02/14/2024 S 112 D $949.07(11) 20,953 D
Common Stock 02/14/2024 S 375 D $950.45(12) 20,578 D
Common Stock 02/14/2024 S 200 D $951.77(13) 20,378 D
Common Stock 12,376 I 2023 GRAT
Common Stock 1,084 I By 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents volume-weighted average price of sales of 439 shares of Company stock on February 14, 2024 at prices ranging from $937.86 to $937.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
2. Represents volume-weighted average price of sales of 226 shares of Company stock on February 14, 2024 at prices ranging from $938.00 to $938.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
3. Represents volume-weighted average price of sales of 750 shares of Company stock on February 14, 2024 at prices ranging from $939.39 to $939.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
4. Represents volume-weighted average price of sales of 4,261 shares of Company stock on February 14, 2024 at prices ranging from $940.06 to $940.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
5. Represents volume-weighted average price of sales of 275 shares of Company stock on February 14, 2024 at prices ranging from $941.09 to $941.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
6. Represents volume-weighted average price of sales of 2,691 shares of Company stock on February 14, 2024 at prices ranging from $943.23 to $943.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
7. Represents volume-weighted average price of sales of 620 shares of Company stock on February 14, 2024 at prices ranging from $944.29 to $944.30. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
8. Represents volume-weighted average price of sales of 95 shares of Company stock on February 14, 2024 at prices ranging from $945.66 to $945.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
9. Represents volume-weighted average price of sales of 240 shares of Company stock on February 14, 2024 at prices ranging from $947.77 to $947.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
10. Represents volume-weighted average price of sales of 150 shares of Company stock on February 14, 2024 at prices ranging from $948.13 to $948.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
11. Represents volume-weighted average price of sales of 112 shares of Company stock on February 14, 2024 at prices ranging from $949.02 to $949.14. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
12. Represents volume-weighted average price of sales of 375 shares of Company stock on February 14, 2024 at prices ranging from $950.37 to $950.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
13. Represents volume-weighted average price of sales of 200 shares of Company stock on February 14, 2024 at prices ranging from $951.61 to $951.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 14, 2024 at each separate price.
/s/**Daniel P. Van Plew 02/16/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.